New Agilent expansion will ‘more than double’ nucleic acid API manufacture
August 10, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Agilent, expansion, manufacturing, oligonucleotide
Agilent Technologies is set to expand its pharmaceutical manufacturing operations with a 20-acre facility in Weld County, Colorado. The facility …
Interim analysis fails to show benefits for Lilly’s abemaciclib in advanced breast cancer
August 10, 2016Research and Development Eli Lilly, abemaciclib, breast cancer
Eli Lilly has announced that, after a pre-planned interim analysis for their Phase III MONARCH2 trial, investigators have decided to …
Valeant stock rises despite weak Q2 results
August 10, 2016Research and Development, Sales and Marketing Valeant, financial results
Valeant Pharmaceuticals’ share price in pre-market trading has risen 7.44% to $24.12 in the wake of its Q2 results announcement. …
Biogen names haemophilia spin-off Bioverativ
August 10, 2016Manufacturing and Production, Research and Development, Sales and Marketing Biogen, bioverativ
Biogen has announced that Bioverativ will be the name of the standalone spin-off of its haemophilia and other blood disorders …
Experimental stem cell treatment shows promise in rheumatoid arthritis
August 10, 2016Research and Development Mesoblast, rheumatoid arthritis, stem cell treatment
Mesoblast has announced results from a Phase II clinical trial evaluating MPC-300-IV in patients with biologic refractory rheumatoid arthritis (RA) …
Old CDF drug not recommended in initial NICE guidance due to lack of evidence
August 10, 2016Research and Development, Sales and Marketing Adcetris, Cancer Drugs Fund, NICE, Takeda, hodgkin's lymphoma
The National Institute for Health and Care Excellence (NICE) has published draft guidance not recommending Takeda’s Adectris (brentuximab vedotin), despite …
NICE recommends Amgen’s Imlygic for advanced skin cancer
August 9, 2016Manufacturing and Production, Sales and Marketing Amgen, Imlygic, NICE, skin cancer
NICE has published its final draft guidance recommending Amgen’s Imlygic (talimogene laherparepvec) for the treatment of advanced melanoma in adults …
Helsinn and MEI Pharma join forces to develop leukaemia drug Pracinostat
August 9, 2016Manufacturing and Production, Research and Development Helsinn, MEI Pharma, Pracinostat, chronic myeloid leukaemia
Swiss pharmaceutical group Helsinn has entered an agreement with MEI Pharma over the licensing, development and commercialisation of Pracinostat (SB939) …
New therapy wins EMA orphan drug designation for ALS
August 9, 2016Manufacturing and Production, Research and Development EMA, Ice Bucket Challenge, ab science, als, masitinib, oprhan drug designation
French pharma company AB Science has announced that the European Medicines Agency has granted orphan drug status to masitinib for …
AstraZeneca’s selumetinib fails to meet primary endpoint in lung cancer trial again
August 9, 2016Manufacturing and Production AstraZeneca, failure, non-small cell lung cancer, phase III, selumetinib, trial failure
AstraZeneca has announced that its MEK 1/2 inhibitor, selumetinib, failed to meet its primary endpoint of progression free survival in …
Management shake-up at Valeant as Papa expands senior team
August 9, 2016Manufacturing and Production, Sales and Marketing Valeant, joseph papa, management, shake up
Joseph Papa continues to remodel the plagued Valeant Pharmaceuticals, as a senior management shake-up has seen several new arrivals and …
FDA approves MSD’s Keytruda for head and neck cancer treatment
August 8, 2016Manufacturing and Production, Research and Development Cancer, FDA, MSD, keytruda
The US Food and Drug Administration (FDA) has approved MSD’s Keytruda (pembrolizumab) for treatment of recurrent or metastatic head and …
SMC reverses decision on Opdivo in advanced skin cancer
August 8, 2016Manufacturing and Production, Research and Development SMC, Scottish Medicines Consortium, melanoma, opdivo, skin cancer
The Scottish Medicines Consortium (SMC) has reversed an earlier decision for Bristol-Myers Squibb’s Opdivo (nivolumab) and has now approved recommended …
Apellis Pharmaceuticals appoints Dr Robert Kim as CMO
August 8, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Apellis, CMO, GSK, Novartis, appointment
Clinical stage complement immunotherapy company Apellis Pharmaceuticals has named its new chief medical officer as Dr Robert Kim. Kim’s primary …
AbbVie files lawsuit against Amgen over Humira copy
August 8, 2016Research and Development, Sales and Marketing AbbVie, Amgen, FDA, Humira, rheumatoid arthritis
Abbvie has filed a patent infringement lawsuit against Amgen over the latter firm’s copy of its Humira (adalimumab) rheumatoid arthritis …
The power of PrEP
August 8, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, PrEP, high court, lifestyle drug
Many among the general public may not have heard about PrEP, or pre-exposure prophylaxis, before last week when a high …
Opdivo and Keytruda set for India launches by end of year
August 8, 2016Sales and Marketing India, keytruda, launch, opdivo
Indian cancer patients could be set to receive two of the world’s leading oncology drugs, MSD’s Keytruda and Bristol-Myers Squibb’s …
‘Game changer’ asthma pill sees significant reduction in severe symptoms
August 8, 2016Research and Development, Sales and Marketing Fevipiprant, Novartis, asthma, university of Leicester
A study at the University of Leicester has found that Fevipiprant (QAW039), the first new asthma pill for nearly 20 …
MSD files Lantus biosimilar with FDA
August 8, 2016Sales and Marketing FDA, Lantus, MK-1293, MSD, application, biosimilar
MSD, known as Merck in the US and Canada, has filed a new drug application with the US Food and …
Shock for BMS as Opdivo misses goal in late-stage lung cancer trial
August 5, 2016Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Checkmate, lung cancer, opdivo
Bristol-Myers Squibb has announced that its much heralded cancer therapy, Opdivo (nivolumab), failed to meet its primary endpoint of progression-free …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
